TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Scinai Immunotherapeutics ( (SCNI) ) is now available.
On March 5, 2025, Scinai Immunotherapeutics announced a $10 million Standby Equity Purchase Agreement with Yorkville Advisors, allowing Scinai to sell its American Depository Shares over a three-year period. This agreement provides Scinai with financial flexibility to support its R&D and CDMO business expansion, enabling the company to strategically access capital as needed without mandatory commitments.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company that focuses on developing inflammation and immunology biological products. It operates two business units: one dedicated to creating nanosized VHH antibodies (nanoAbs) for diseases with significant unmet needs, and a boutique CDMO offering drug development and manufacturing services.
YTD Price Performance: -2.85%
Average Trading Volume: 12,267
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.85M
Learn more about SCNI stock on TipRanks’ Stock Analysis page.